시장보고서
상품코드
1147336

만성적 후각 및 미각 상실 시장 : 시장 인사이트, 역학, 시장 예측(-2032년)

Chronic Smell and Flavor Loss - Market Insight, Epidemiology And Market Forecast - 2032

발행일: | 리서치사: DelveInsight Business Research LLP | 페이지 정보: 영문 141 Pages | 배송안내 : 1-2일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

주요 7개국의 만성적 후각 및 미각 상실 시장 규모는 2021년에 2억 1,400만 달러로 평가되었습니다. 이 시장은 앞으로도 한층 더 확대될 것으로 예측됩니다.

주요 7개국의 만성적 후각 및 미각 상실 시장에 대해 조사했으며, 시장 개요와 함께 역학, 환자 동향, 새로운 치료법, 2032년까지 시장 규모 예측 및 의료 미충족 요구 등의 정보를 제공합니다.

목차

제1장 주요 인사이트

제2장 보고서 서론

제3장 만성적 후각 및 미각 상실 시장 개요

제4장 만성적 후각 및 미각 상실 개요

제5장 질환의 배경과 개요

  • 서론
  • 분류
    • 후각 장애
    • 미각 장애
  • 징후와 증상
  • 병인과 위험 요인
  • 생리학과 병인
  • COVID-19 후각 장애와 미각 장애
  • 만성적 후각 및 미각 상실 진단
  • 감별 진단
  • 치료
  • 진료 가이드라인

제6장 역학과 환자수

  • 700만명 만성적 후각 및 미각 상실 유병률 인구
  • 주요 조사 결과
  • 가정과 근거
  • 미국
  • 유럽 5개국
  • 일본

제7장 환자 동향

제8장 새로운 치료법

제9장 만성적 후각 및 미각 상실 : 주요 7개국 시장 분석

  • 주요 조사 결과
  • 주요 7개국의 만성적 후각 및 미각 상실 시장 규모
  • 시장 전망
  • 미국 시장 규모
  • 유럽 5개국 시장
  • 일본

제10장 SWOT 분석

제11장 미충족 요구

제12장 KOL(Key Opinion Leader)의 견해

제13장 두자어와 약어

제14장 부록

제15장 DelveInsight의 서비스 내용

제16장 면책사항

제17장 DelveInsight에 대해

LSH 22.11.11

DelveInsight's 'Chronic smell and flavor loss - Market Insights, Epidemiology, and Market Forecast - 2032' report delivers an in-depth understanding of chronic smell and flavor loss, historical and forecasted epidemiology, as well as the market trends in the United States, the EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

The chronic smell and flavor loss market report provides current treatment practices, emerging drugs, market share of the individual therapies, and current and forecasted chronic smell and flavor loss symptoms market size from 2019 to 2032, segmented by seven major markets. The report also covers current chronic smell and flavor loss symptoms treatment practice/algorithms, and unmet medical needs to curate the best opportunities. It assesses the underlying potential of the market.

Geography Covered:

  • The United States
  • The EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019-2032.

Chronic smell and flavor loss Disease Understanding and Treatment Algorithm

Chronic smell and flavor loss Overview

Disorders of smell and taste challenge the ability to consume safe and healthy diets as well as enjoy eating and food-related behaviors. These disorders impair the ability to sense warning odors in foods and the environment and hinder the quality of life (QoL)-related to social interactions, eating, and feelings of well-being. These are not life-threatening and usually represent significant underlying diseases; therefore, they are often overlooked by the medical community.

Chronic smell and flavor loss Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnoses available in the Chronic smell and flavor loss market to treat the condition. It also provides country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.

The DelveInsight Chronic smell and flavor loss market report thoroughly understands Chronic smell and flavor loss symptoms by including disease definition, symptoms, causes, physiology, and diagnosis. It also provides chronic smell and flavor loss treatment algorithms and treatment guidelines for chronic smell and flavor loss symptoms in the US, Europe, and Japan.

There are only limited treatments available for smell disorders, and proven effective treatment is only available where nasal illnesses cause smell disorders. The focus is on surgical treatment (polypectomy, pansinus procedures) and the application of corticosteroids. Regarding surgical and non-surgical treatments, the so-called olfactory cleft disease is particularly difficult to treat; this involves isolated swelling in the olfactory cleft area.

A few major unmet needs in the market include maintaining a balance between pain relief and side effects, lack of standardized tools to assess functional impairment, gaps in proper diagnosis and understanding, challenging diagnosis, absence of pain biomarkers, misperception and limited knowledge and lack of individualized treatment

Chronic smell and flavor loss Epidemiology

The Chronic smell and flavor loss symptoms epidemiology division provides insights into the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and its trends and assumptions.

Key Findings

The total prevalent cases of Chronic smell and flavor loss patients in the 7MM will increase during the study period, i.e., 2019-2032.

The disease epidemiology covered in the report provides historical as well as forecasted Chronic smell and flavor loss symptoms epidemiology segmented as the total prevalent cases of chronic smell and flavor loss, total diagnosed cases of chronic smell and flavor loss (including COVID-19 patients), age-specific cases of chronic smell and flavor loss, and etiology-specific cases of Chronic smell and flavor loss. The report includes the prevalent cases scenario of Chronic smell and flavor loss in the 7MM covering the United States, the EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Country-wise Chronic smell and flavor loss Epidemiology

The epidemiology segment also provides the Chronic smell and flavor loss epidemiology data and findings across the United States, the EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The prevalent cases of Chronic smell and flavor loss associated in 7MM countries were around 214 million in 2021.

Chronic smell and flavor loss Drug Chapters

The Chronic smell and flavor loss report's drug chapter segment encloses the detailed analysis of Chronic smell and flavor loss early-stage (Phase II and III) pipeline drugs. It also helps understand the Chronic smell and flavor loss clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Chronic smell and flavor loss Emerging Drugs

Cyrano Therapeutics has developed a nasal spray to treat and restore the sense of smell and flavor in those who have experienced a chronic loss of those senses. The composition comprises phosphodiesterase (PDE) inhibitors formulated for intranasal administration. The major mechanism underlying all pathologies responsible for smell and flavor loss is similar. It involves inhibition of stem cell activation, which normally occurs by the action of adenylyl cyclase III through cAMP and cGMP.

Other Products detailed in the report…

Chronic smell and flavor loss Market Outlook

The report's Chronic smell and flavor loss market outlook helps understand the historic, current, and forecasted Chronic smell and flavor loss market trends by analyzing the impact of current therapies on the market, unmet needs, and demand for better technology.

This segment gives a thorough detail of the Chronic smell and flavor loss market trend of each marketed drug and early-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to view the market at first sight.

According to DelveInsight, the chronic smell and flavor loss market in the 7MM is expected to grow steadily during the study period 2019-2032.

There are only limited treatments available for smell disorders, and proven effective treatment is only available where nasal illnesses cause smell disorders. The focus is on surgical treatment (polypectomy, pansinus procedures) and the application of corticosteroids. Regarding surgical and non-surgical treatments, the so-called olfactory cleft disease is particularly difficult to treat; this involves isolated swelling in the olfactory cleft area. Concerning the treatment of other non-sinonasal smell disorders, treatments, which are not proven to be efficient include treatment with estrogens, zinc, minocycline, and vitamin A at 10,000 i.e., oral over 4 weeks.

Treatments with corticoids and vitamin A are often attempted, but there is a lack of convincing clinical studies. The same applies to studies involving acupuncture. Only for zinc gluconate (140 mg/day for 3 months) is data available on the therapeutic effectiveness in idiopathic dysgeusia. For BMS, tricyclic antidepressants (amitriptyline, imipramine) improve the abnormal sensation. Successful treatments have also been carried out with clonazepam or diazepam; gabapentin appears ineffective. 

Key Findings

This section includes a glimpse of the Chronic smell and flavor loss market in the 7MM.

The Chronic smell and flavor loss market size in the seven major markets was approximately USD 2.8 billion in 2021.

The United States Market Outlook

This section provides the total chronic smell and flavor loss market size and market size by therapies in the United States.

The United States accounts for the largest market size of chronic smell and flavor loss compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

The EU5 Countries: Market Outlook

The total chronic smell and flavor loss market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total chronic smell and flavor loss market size and market size by therapies in Japan are also mentioned.

Chronic smell and flavor loss Drugs Uptake

This section focuses on the uptake of the potential drugs recently launched or expected to be launched in the market during 2019-2032. The analysis covers the chronic smell and flavor loss market uptake by drugs, patient uptake by therapies, and sales of each drug.

This helps understand the drugs with the most rapid uptake, the reasons behind the maximal use of new drugs, and the comparison of the drugs based on market share and size, which will again be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Chronic smell and flavor loss Pipeline Development Activities

The report provides insights into the therapeutic candidate in Phase I, II, and III stages. It also analyses Chronic smell and flavor loss key players involved in developing targeted therapeutics.

Major market players include Cyrano Therapeutics, among others.

Pipeline Development Activities

The report covers detailed information on collaborations, acquisitions, mergers, licensing, and patent details for Chronic smell and flavor loss emerging therapies.

Reimbursement Scenario in Chronic smell and flavor loss

Proactively approaching reimbursement can positively impact both during the early stages of product development and after product launch. The report considers reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select markets with better market access can be a critical business and price strategy.

KOL Views

To keep up with current market trends, we take KOLs and SMEs' opinions working in the chronic smell and flavor loss domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or chronic smell and flavor loss market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform a Competitive and Market Intelligence analysis of the chronic smell and flavor loss Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

  • The report covers a descriptive overview of chronic smell and flavor loss, explaining its causes, signs and symptoms, physiology, and currently available therapies.
  • Comprehensive insight into the chronic smell and flavor loss epidemiology and treatment in the 7MM.
  • Additionally, an all-inclusive account of the current and emerging therapies for chronic smell and flavor loss is provided, along with the assessment of new therapies that will impact the current treatment landscape.
  • A detailed review of the chronic smell and flavor loss market, historical and forecasted, is included in the report, covering drug outreach in the 7MM.
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global Chronic smell and flavor loss market.

Report Highlights:

  • In the coming years, the chronic smell and flavor loss market is set to change due to the rising awareness of the disease, the development of diagnostic techniques, and the favorable environment from regulators for innovative first-in-class curative drugs, and are likely to expand the market's size and enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence chronic smell and flavor loss R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for chronic smell and flavor loss. The launch of emerging therapies will significantly impact the chronic smell and flavor loss market.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase I, II, and III), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, and launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Chronic smell and flavor loss Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Chronic smell and flavor loss Pipeline Analysis
  • Chronic smell and flavor loss Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Chronic smell and flavor loss Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Chronic smell and flavor loss Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Chronic smell and flavor loss Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness

Key Questions

Market Insights:

  • What was the chronic smell and flavor loss Market share (%) distribution in 2019, and how would it look in 2032?
  • What would be the chronic smell and flavor loss total market size and market size by therapies across the 7MM during the forecast period (2019-2032)?
  • What are the key findings of the market across the 7MM, and which country will have the largest chronic smell and flavor loss market size during the forecast period (2019-2032)?
  • At what CAGR the chronic smell and flavor loss market is expected to grow in the 7MM during the forecast period (2019-2032)?
  • What would be the chronic smell and flavor loss market outlook across the 7MM during the forecast period (2019-2032)?
  • What would be the chronic smell and flavor loss market growth till 2032, and what will be the resultant market size in 2032?

Epidemiology Insights:

  • What are the disease risk, burdens, and unmet needs of chronic smell and flavor loss?
  • What is the historical chronic smell and flavor loss patient pool in seven major markets covering the United States, the EU5 (Germany, Spain, France, Italy, the UK), and Japan?
  • What would be the forecasted patient pool of chronic smell and flavor loss in seven major markets covering the United States, the EU5 (Germany, Spain, France, Italy, the UK), and Japan?
  • Out of all 7MM countries, which country would have the largest prevalent population of chronic smell and flavor loss during the forecast period (2019-2032)?
  • At what CAGR is the population expected to grow in the 7MM during the forecast period (2019-2032)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of chronic smell and flavor loss along with the approved therapy?
  • What are the current treatment guidelines for treating chronic smell and flavor loss in the US, Europe, and Japan?
  • What are chronic smell and flavor loss marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
  • How many companies are developing therapies for the treatment of chronic smell and flavor loss?
  • How many therapies are developed by each company for the treatment of chronic smell and flavor loss?
  • How many emerging therapies are in the mid-stage and late stages of development to treat chronic smell and flavor loss?
  • What are the key collaborations (Industry-Industry, Industry-Academia), mergers and acquisitions, and licensing activities related to chronic smell and flavor loss therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for chronic smell and flavor loss and their status?
  • What key designations have been granted for emerging therapies for chronic smell and flavor loss?
  • What are the global historical and forecasted markets for chronic smell and flavor loss?

Reasons to buy:

  • The report will help develop business strategies by understanding trends shaping and driving the chronic smell and flavor loss market.
  • To understand the future market competition in the chronic smell and flavor loss market and an Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for chronic smell and flavor loss in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • Identifying strong upcoming players in the market will help devise strategies that will help get ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the chronic smell and flavor loss market.
  • To understand the future market competition in the chronic smell and flavor loss market.

Table of Contents

1. Key Insights

2. Report Introduction

3. Chronic Smell and Flavor Loss Market Overview at a Glance

  • 3.1. Market Share (%) Distribution of Chronic Smell and Flavor Loss in 2019
  • 3.2. Market Share (%) Distribution of Chronic Smell and Flavor Loss in 2032

4. Executive Summary of Chronic Smell and Flavor Loss

5. Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Classification
    • 5.2.1. Smell disorders
    • 5.2.2. Taste disorders
  • 5.3. Signs and Symptoms
    • 5.3.1. Anosmia or hyposmia
    • 5.3.2. Dysgeusia
    • 5.3.3. Ageusia
  • 5.4. Etiology and Risk Factors
    • 5.4.1. Etiology of taste disorders
    • 5.4.2. Etiology of OD
  • 5.5. Physiology and Pathogenesis
    • 5.5.1. Sense of olfaction and pathophysiology of olfactory disorders
    • 5.5.2. Sense of gustation and pathophysiology of gustatory disorders
  • 5.6. Smell and Taste Disorders in COVID-19
  • 5.7. Diagnosis of Chronic Smell and Flavor Loss
    • 5.7.1. Physical examination and self-assessment tools
    • 5.7.2. Psychophysical assessment
    • 5.7.3. Imaging tests
    • 5.7.4. Other tests
  • 5.8. Differential Diagnosis
    • 5.8.1. Ageusia
    • 5.8.2. Anosmia
  • 5.9. Treatment
    • 5.9.1. Treatment of olfactory disorders
    • 5.9.2. Treatment of taste disorders
  • 5.10. Clinical Practice Guidelines
    • 5.10.1. Clinical Practice Guidelines for the Management of OD by the Japanese Rhinologic Society
    • 5.10.2. Management of New-Onset Loss of Sense of Smell During the COVID-19 Pandemic - BRS Consensus Guidelines

6. Epidemiology and Patient Population

  • 6.1. The 7MM Total Prevalent Population of Chronic Smell and Flavor Loss
  • 6.2. Key Findings
  • 6.3. Assumptions and Rationale
  • 6.4. The United States
    • 6.4.1. Total Prevalent Cases of Chronic Smell and Flavor Loss in the United States
    • 6.4.2. Total Diagnosed Cases of Chronic Smell and Flavor Loss in the United States
    • 6.4.3. Gender-specific Diagnosed Cases (excluding COVID-19 patients) of Chronic Smell and Flavor Loss in the United States
    • 6.4.4. Age-specific Diagnosed Cases (excluding COVID-19 patients) of Chronic Smell and Flavor Loss in the United States
    • 6.4.5. Etiology-specific (excluding COVID-19-related patients) Cases of Chronic Smell and Flavor Loss in the United States
  • 6.5. The EU5
    • 6.5.1. Total Prevalent Cases of Chronic Smell and Flavor Loss in the EU5
    • 6.5.2. Total Diagnosed Prevalent Cases of Chronic Smell and Flavor Loss in the EU5
    • 6.5.3. Gender-specific Diagnosed Cases of Chronic Smell and Flavor Loss in the EU5
    • 6.5.4. Age-specific Diagnosed Cases of Chronic Smell and Flavor Loss in The EU5
    • 6.5.5. Etiology-specific Cases of Chronic Smell and Flavor Loss in the EU5
  • 6.6. Japan
    • 6.6.1. Total Prevalent Cases of Chronic Smell and Flavor Loss in Japan
    • 6.6.2. Total Diagnosed Cases of Chronic Smell and Flavor Loss in Japan
    • 6.6.3. Gender-specific Diagnosed Cases of Chronic Smell and Flavor Loss in Japan
    • 6.6.4. Age-specific Diagnosed Cases of Chronic Smell and Flavor Loss in Japan
    • 6.6.5. Etiology-specific Cases of Chronic Smell and Flavor Loss in Japan

7. Patient Journey

8. Emerging Therapies

  • 8.1. Key Cross Competition
  • 8.2. CYR-064: Cyrano Therapeutics
    • 8.2.1. Drug description
    • 8.2.2. Other development activities
    • 8.2.3. Clinical development
    • 8.2.4. Product profile

9. Chronic Smell and Flavor Loss: The Seven Major Market Analysis

  • 9.1. Key Findings
  • 9.2. Market Size of Chronic Smell and Flavor Loss in the 7MM
  • 9.3. Market Outlook
  • 9.4. The United States Market Size
    • 9.4.1. Total Market Size of Chronic Smell and Flavor Loss in the United States
    • 9.4.2. Market Size of Chronic Smell and Flavor Loss by Therapies in the United States
  • 9.5. The EU5 Market
    • 9.5.1. Total Market Size of Chronic Smell and Flavor Loss in the EU5
    • 9.5.2. Market Size of Chronic Smell and Flavor Loss by Therapies in the EU5
  • 9.6. Japan
    • 9.6.1. Total Market Size of Chronic Smell and Flavor Loss in Japan
    • 9.6.2. Market Size of Chronic Smell and Flavor Loss by Therapies in Japan

10. SWOT Analysis

11. Unmet Needs

12. KOL Views

13. Acronyms and Abbreviations

14. Appendix

  • 14.1. Bibliography
  • 14.2. Report Methodology

15. DelveInsight Capabilities

16. Disclaimer

17. About DelveInsight

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제